Target- |
MechanismCell membrane permeability enhancers |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseWithdrawn |
First Approval Ctry. / Loc.United States |
First Approval Date31 May 2002 |
100 Clinical Results associated with VESSELON SPV LLC
0 Patents (Medical) associated with VESSELON SPV LLC
100 Deals associated with VESSELON SPV LLC
100 Translational Medicine associated with VESSELON SPV LLC